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Abstract
Objectives. Smoking is a major risk factor for the development of both cardiovascular disease (CVD) and RA and
may cause attenuated responses to anti-rheumatic treatments. Our aim was to compare disease activity, CVD risk
factors and CVD event rates across smoking status in RA patients.
Methods. Disease characteristics, CVD risk factors and relevant medications were recorded in RA patients without
prior CVD from 10 countries (Norway, UK, Netherlands, USA, Sweden, Greece, South Africa, Spain, Canada and
Mexico). Information on CVD events was collected. Adjusted analysis of variance, logistic regression and Cox mod-
els were applied to compare RA disease activity (DAS28), CVD risk factors and event rates across categories of
smoking status.
Results. Of the 3311 RA patients (1012 former, 887 current and 1412 never smokers), 235 experienced CVD
events during a median follow-up of 3.5 years (interquartile range 2.5–6.1). At enrolment, current smokers were
more likely to have moderate or high disease activity compared with former and never smokers (P<0.001 for
both). There was a gradient of worsening CVD risk factor profiles (lipoproteins and blood pressure) from never to
former to current smokers. Furthermore, former and never smokers had significantly lower CVD event rates com-
pared with current smokers [hazard ratio 0.70 (95% CI 0.51, 0.95), P¼0.02 and 0.48 (0.34, 0.69), P<0.001, re-
spectively]. The CVD event rates for former and never smokers were comparable.
Conclusion. Smoking cessation in patients with RA was associated with lower disease activity and improved lipid
profiles and was a predictor of reduced rates of CVD events.
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Patients with RA experience an increased risk of cardio-
vascular disease (CVD) as a result of an intricate inter-
play between chronic inflammation and traditional CVD
risk factors [1–5]. This risk is comparable to that of
patients with diabetes mellitus [6].
A strong link between tobacco smoking and CVD
events has been identified in the general population as
well as in patients with RA [3, 7]. Indeed, a meta-
analysis from 2015 revealed that RA patients who were
smokers had a 50% higher CVD morbidity compared
with non-smokers [3]. Moreover, smoking is a well-
established modifiable risk factor in the development of
RA and causes accelerated disease progression as well
as an attenuated response to DMARDs [8–11]. Thus
smoking cessation in RA patients may represent an op-
portunity to ‘kill two birds with one stone’.
Unsurprisingly, smoking cessation is recommended in
the European Society of Cardiology guidelines for CVD
prevention, the EULAR recommendations for CVD risk
management in RA and the EULAR recommendations
for the management of early arthritis [12–14].
In the general population, smoking is associated with
increased lipid levels, while smoking cessation leads to
improved lipid profiles [15, 16]. However, this associ-
ation has not been investigated in patients with RA. For
the general population, a 50% CVD risk reduction has
been observed within the first 2 years following smoking
cessation, while risk of ischaemic stroke is comparable
to that of never smokers 5 years after smoking cessation
[17–19]. Data on the effect of smoking cessation and
prevention of future CVD events in RA are limited to a
retrospective medical records–based study that found a
significant reduction in the risk of hospitalization due to
CVD events in former compared with never smokers
[20].
The aim of this study was to compare disease activity,
CVD risk factors and the risk of future CVD events in RA




The study population has previously been described in
detail [21, 22]. In short, the cohort consists of patients
with physician diagnosis of RA (1987 or 2010 American
College of Rheumatology criteria for RA [23, 24]) from
10 countries (UK, Norway, Netherlands, USA, Sweden,
Greece, South Africa, Spain, Canada and Mexico) for
whom both traditional and RA-specific CVD risk factors,
including RA disease activity measures, as well as drugs
used for treatment of RA were collected [21].
The study was carried out according to the Declaration
of Helsinki and was approved by the ethical boards/com-
mittees at each centre. Informed consent was obtained
from the study participants where required. The ATACC-
RA (A TransAtlantic Cardiovascular risk Calculator for
Rheumatoid Arthritis) register was built at the Mayo Clinic
after anonymous (de-identified) patient data were trans-
ferred from each centre to the Mayo Clinic. The ATACC-
RA register was transferred to Diakonhjemmet, Oslo,
Norway. In addition, a General Data Protection
Regulation evaluation has been approved by the Data
Protection Officer at Diakonhjemmet (25/4-2019). This
study was approved by the South-East Health Authorities
Ethical Committee (2019/807).
Variable definitions
The following CVD risk factors were collected at base-
line: age, sex, smoking status (current, former, never),
systolic and diastolic blood pressure (BP), lipid levels
[total cholesterol (TC), high-density lipoprotein choles-
terol (HDLC), low-density lipoprotein cholesterol (LDLC),
triglycerides], BMI and a family history of CVD, diabetes
mellitus and hypertension. Use of lipid-lowering and
antihypertensive medications was also recorded [21,
22]. In addition, non-HDL levels were calculated by sub-
tracting HDLC from TC.
The following RA-specific factors were recorded: RF
positivity, ACPA positivity, ESR, CRP and 28-joint DAS
using ESR (DAS28-ESR) [25]. RF and ACPA (only avail-
able in a subset of patients) were considered positive
based on the tests performed at each centre. CRP was
unavailable in one cohort, and DAS28 was unavailable in
another cohort. Data on the use of NSAIDs, cyclooxyge-
nase-2 inhibitors, glucocorticoids and synthetic and bio-
logic DMARDs were collected [21, 22].
CVD events during follow-up were defined according
to guidelines as acute coronary syndrome (unstable an-
gina pectoris, ST elevation and non-ST elevation myo-
cardial infarction), chronic ischaemic heart disease
(stable angina pectoris), coronary revascularization (e.g.
percutaneous coronary intervention and coronary artery
bypass grafting), coronary death, other CVD death,
cerebrovascular events (ischaemic cerebrovascular acci-
dent and transient ischemic attack) and peripheral vas-
cular events (with and without revascularization
procedures, peripheral artery disease) [21, 22]. Cases of
confirmed cerebral haemorrhage, non-coronary cardiac
death, non-ischemic cardiovascular disease, heart
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failure and aortic aneurysm were not included as CVD
events [21, 22].
Statistical methods
Descriptive statistics are expressed as numbers (%) for
dichotomized variables, while mean (S.D.) and median
with interquartile range (IQR) were applied for normally
and non-normally distributed continuous variables, re-
spectively. Independent samples t-tests, analysis of vari-
ance and v2 tests were applied as appropriate for crude
group comparisons. Non-normally distributed variables
were logarithmically transformed before conducting the
analyses.
Analyses of covariance were applied to perform
adjusted comparisons of RA-specific and cardiovascular
variables across smoking status. All analyses were
adjusted for age and sex, while lipoprotein and BP vari-
ables were also adjusted for statin and antihypertensive
use, respectively.
The first occurrence of a CVD event was compared
across smoking status in adjusted Cox proportional haz-
ards regression models. Three different models adjusted
for age, sex, antihypertensive and lipid-lowering therapy
use were constructed in order to compare former vs
current smokers, former vs never smokers and current
vs never smokers. In addition, an adjusted Cox model
that included all three smoking statuses (former, current
and never) was plotted on a graph to visualize cumula-
tive CVD event rates. Proportional hazard assumptions
were tested and confirmed graphically (log-log curves).
The analyses included only the first CVD event in each
patient; subsequent CVD events in the same patient
were not included.
To examine differences in RA disease activity across
smoking status, patients were divided into either remis-
sion/low disease activity or moderate/high disease activ-
ity according to the DAS28 [25]. Results are presented
as crude percentages in a bar graph with P-values from
logistic regression adjusted for age, sex and disease
duration.
Two-sided P-values <0.05 were considered signifi-
cant. All analyses were performed using the Statistical
Package for the Social Sciences for Windows, version
21.0 (IBM, Armonk, NY, USA).
Results
A total of 3311 patients were included in the present
study, including 1012 former smokers, 887 current
smokers and 1412 never smokers. The median follow-
up was 3.54 years (interquartile range 2.5–6.1), which
was comparable in the three groups (data not shown).
During follow-up, 235 patients experienced one or more
CVD events. As shown in Table 1, there were significant
differences in age (ranging from 53.6 years among cur-
rent smokers to 58.8 years in the former smokers) and
female sex (ranging from 86.5% in those who had never
smoked to 62.8% among those who were former
smokers) across smoking status groups. Furthermore,
current smokers had lower BMI, longer disease dura-
tions and used less lipid-lowering and antihypertensive
therapies compared with former and never smokers.
There were also significant differences in the use of vari-
ous anti-rheumatic drugs among patients with different
smoking statuses.
There were no significant differences in ESR, CRP or
DAS28 across smoking status (Table 2).
However, when patients were clustered into groups
according to their DAS28 scores (remission/low disease
activity vs moderate/high disease activity; Fig. 1), a
greater proportion of current smokers had moderate or
high disease activity (70.6%) compared with former and
never smokers (62.5% and 60.4%, respectively), which
remained highly significant after adjustment for age, sex
and disease duration (P< 0.001 for both).
Patients who had never smoked had more favourable
CVD risk profiles than former and current smokers after
adjusting for age, sex and use of relevant CVD prevent-
ive medication (Table 2). RA patients who had never
smoked had significantly lower TC, triglycerides, LDLC,
non-HDLC, systolic BP and diastolic BP, while their
HDLC levels were significantly higher compared with the
two other groups. Moreover, former smokers had signifi-
cantly lower triglycerides, LDLC and non-HDLC com-
pared with current smokers. Former smokers also had
significantly higher HDLC than current smokers.
However, there were no significant differences in systol-
ic or diastolic BP levels when comparing former and
current smokers.
Cox models adjusted for age, sex, lipid-lowering
therapies and antihypertensive use are presented in
Fig. 2. Compared with current smokers, former and
never smokers had a 30% (P¼ 0.022) and 50%
(P<0.001) lower risk of future CVD, respectively.
However, the risk for future CVD was not significantly
different in former and never smokers. These results
were robust in additional Cox models that included add-
itional covariates (data not shown).
Discussion
In a large cohort of RA patients, we showed that the
risk of future CVD events is significantly lower in RA
patients who have stopped smoking compared with
those who continue smoking. Interestingly, while there
were no significant differences in CVD event rates
across never smokers and former smokers, the event
rate was significantly higher among RA patients who
were current smokers. This difference may be explained,
at least partly, by a continuum in terms of worsening
CVD risk factor profiles from never smokers to former
smokers to current smokers in RA patients and is sup-
ported by existing evidence on the impact of smoking
on CVD events and risk factor profiles [17, 26, 27].
Another cause may be that smokers were more likely to
have higher disease activity, which is an important RA-
associated CVD risk factor.
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We did not observe significant differences in DAS28
when it was considered as a continuous variable across
smoking status groups. However, former smokers were
more likely to be in remission or have moderate disease
activity compared with current smokers. This was also
found in a register study comparing disease activity
across smoking status among anti-CCP-positive RA
patients in the USA where never and former smokers
had lower disease activity compared with current smok-
ers [28]. In contrast, Fisher et al. [29] reported that in a
North American population of 16 521 RA patients, smok-
ing status did not influence disease activity. However,
this study used the composite measure clinical disease
activity index, which does not include acute phase reac-
tants. In a Swedish RA cohort, Andersson et al. [30]
reported that RA disease activity measures, including
HAQ, visual analogue scale pain or DAS28, did not im-
prove following smoking cessation. This study used
DAS28 as a composite score for disease activity
(n¼1460), while interpretation of the results were also
hampered by the retrospective design and the fact that
only 127 patients stopped smoking after inclusion [30].
In a cohort study by Casta~neda et al. [31] it was sug-
gested that prolonged smoking exposure may favour a
pro-inflammatory state leading to increased disability
and higher risk of CVD in these patients.
Previous studies from the general population have pre-
sented evidence that despite weight gain, HDLC levels
tend to increase in persons who quit smoking [16, 32].
To date, the effect of smoking cessation on other lipopro-
tein fractions, such as LDLC, is inconclusive [32]. To our
knowledge, the present study provides the first data on
the possible effect of smoking cessation on lipid levels in
RA patients. It is well documented that inflammation sup-
presses lipoprotein levels and, accordingly, there is a ten-
dency that treatment with inflammation-lowering drugs
leads to rising lipid levels [13, 33]. In our study, current
smokers were more likely to have moderate or high
disease activity, which would presumably lead to
decreased lipid levels. Despite this, we found that the lip-
oproteins were higher in current smokers, apart from
HDLC, which was lower, suggesting a beneficial effect of
smoking cessation on lipid profiles in RA patients.
Although the CVD preventive effect of smoking cessa-
tion is well documented in the general population [34–
36], the information about the impact of smoking cessa-
tion in RA patients has until now been limited [20]. In a
study by Joseph et al. [20], UK primary care medical
records were explored to identify smoking habits, pre-
scription of smoking cessation therapy and hospitaliza-
tion among some 5000 RA patients. In adjusted
analyses, the authors found that the hazard ratio (HR) of
hospitalization for CVD events in current vs never smok-
ers was 2.23, while the corresponding HR for current vs
former smokers was 1.51. Our findings are along the
same lines, as we demonstrated that the HR for a CVD
event in former vs current smokers was 0.70 in adjusted
analyses, while it was 0.48 in never vs current smokers.
However, in contrast to the study by Joseph et al. [20],
we did not find a significant difference in the CVD event
rates across former and never smokers, although there
was a numerical trend in the same direction as the find-
ings in the study by Joseph et al. This inconsistent find-
ing may be explained by the fact that our data did not
include time since smoking cessation nor pack-years of
smoking. Nonetheless, our results back up the hypoth-
esis that smoking cessation in RA patients leads to
reduced CVD risk, approaching the low risk observed in
never smokers. The underlying mechanisms for this risk
reduction may lie, at least partly, in the other results
from our study; in particular, improved CVD risk factor
profiles and reduced disease activity [37, 38].
Furthermore, smoking has direct effects on the vessel
walls, which are known to aggravate atherogenesis,
including increased arterial stiffness and endothelial dys-
function, which was not measured in our study [39, 40].







Age, mean (S.D.), years 58.77 (12.30)** 53.59 (11.72)** 55.33 (15.41)*
Sex (female), n (%) 636 (62.8)* 596 (67.2)** 1221 (86.5)**
BMI, mean (S.D.) 27.47 (4.90)** 25.95 (4.74)* 27.03 (5.13)**
Disease duration, years, median (IQR) 1.74 (0.25–10.59)** 4.22 (0.07–6.00)* 3.08 (0.45–11.00)**
RF positive, n (%) 656 (66.3)* 632 (72.3) 885 (63.9)**
Anti-CCP positive, n (%) 597 (61.0) 529 (63.3)* 766 (56.4)*
Extra-articular RA, n (%) 48 (6.3) 42 (5.9) 82 (8.1)
Statin, n (%) 111 (11.0)* 69 (7.8) 175 (12.4)**
Anti-hypertensive, n (%) 220 (21.7)** 137 (15.5) 331 (23.5)**
MTX, n (%) 398 (39.7)** 263 (29.8)* 635 (45.1)**
HCQ, n (%) 128 (12.7) 95 (10.8)** 287 (20.4)**
DMARD, n (%) 515 (51.1)** 368 (41.6)** 824 (58.5)**
Biologic, n (%) 155 (15.4)* 111 (12.6) 250 (17.8)**
Steroids, n (%) 240 (23.8) 215 (24.3)* 412 (29.3)*
*P<0.05, **P<0.001.
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Our finding that smoking cessation is associated with
lower RA disease activity further supports the import-
ance of smoking cessation in RA patients. The benefits
from smoking cessation on RA disease-specific out-
comes and long-term effects on RA disease have been
investigated to a limited extent. Still, it is currently
advised that rheumatology health professionals encour-
age smoking cessation in RA patients [12, 13, 41]. To
our knowledge there is only one published pilot study
and one ongoing randomized controlled trial on smoking
cessation in patients with RA [42, 43].
The strengths of this study are that we have a large
sample size including several cohorts of patients with
RA from 10 different countries from different continents.
This makes the results internationally transferable and
not just limited to a specific geographical area. The
cohorts included were either population based or
applied enrolment of consecutive patients, a factor that
could reduce the risk of selection bias. This international
study format could be considered a strength since the
results may be regarded as more likely to be generaliz-
able and not limited to a specific country or area. In
addition, within the cohort there were a large number of
CVD events, which strengthens our results.
Several limitations should also be considered for inter-
pretation of our results. First, smoking cessation was
self-reported. Despite the fact that self-reported out-
comes may vary in quality and reliability, existing evi-
dence supports the validity of self-reported smoking
status [44–46]. Second, smoking status data was col-
lected at baseline and time of smoking cessation, smok-
ing duration and pack-years were not collected. Hence
we could not assess the dose response and time from
smoking cessation to a CVD event. Furthermore, the
fact that we did not have access to follow-up data on
smoking cessation during the study period is a limitation
since we do not know which patients may have stopped
or reinitiated smoking after baseline. Thus, hypothetical-
ly, if more people had stopped smoking during follow-
up this would have strengthened our results further. In
case of the opposite, that more patients had started
smoking after the baseline visit, our results regarding
smoking cessation would still be significant. Third, this
is a study evaluating the effect of lifestyle-related
changes on future CVD events, and although we have
made an effort to adjust our analyses for relevant con-
founders, we cannot exclude the possibility that other
concurrent non-measured lifestyle changes (e.g.
increased frequency of physical activity and nutrition
factors) may have confounded our results. Moreover, we
did not have available data to investigate possible differ-
ences in socio-economic status or psychological traits,
such as conscientiousness, which may have influenced
our results. Differences in the latter variables may also
be possible explanations for the discrepancies observed
across smoking status in the use of cardioprotective
and anti-rheumatic medications.
In conclusion, smoking cessation appears to have
several beneficial effects in patients with RA. Our data
suggest that patients who stop smoking experience
improved RA disease activity, a more favourable lipid
profile and lower frequency of CVD events. We argue
that these findings underline the importance of a larger
focus among health professionals on recommending
and encouraging smoking cessation in patients with RA.
FIG. 2 Adjusted Cox proportional hazards regression
models comparing CVD risk across smoking status in
RA patients
FIG. 1 Disease activity across smoking status
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and AGS outlined the hypothesis, analysed the data and
drafted the first version of the manuscript. SR and GW
contributed substantially to the subsequent versions. All
authors contributed to the analyses and interpretation of
the data and read and commented on drafts and
approved the final version of the manuscript. IKR was
supported by funding from Trygfonden (ID: 119298).
Funding: This work was supported by a collaborative
agreement for independent research from Eli Lilly. Eli
Lilly had no role in the study design, data collection and
analysis, decision to publish or preparation of the
manuscript.
Disclosure statement: TKK has received fees for speak-
ing and/or consulting and/or received research funding
to Diakonhjemmet Hospital from AbbVie, Biogen,
Celltrion, Eli Lilly, MSD, Mylan, Novartis, Oktal, Orion
Pharma, Hospira/Pfizer, Sandoz, Sanofi and UCB. CAH
has received research funding from Pfizer Canada and
UCB. MAGG received grants/research support from
AbbVie, MSD, Jansen and Roche and consultation
fees/participation in company-sponsored speakers
bureaus from Pfizer, Lilly, Sobi, Celgene, Novartis,
Roche and Sanofi. AGS received speaker honoraria
and/or consulting fees from KPMG, Novartis, Bayer
and AbbVie.
References
1 Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman
AJ, Lacaille D. Risk of incident cardiovascular events
in patients with rheumatoid arthritis: a meta-analysis
of observational studies. Ann Rheum Dis 2012;71:
1524–9.
2 Schieir O, Tosevski C, Glazier RH, Hogg-Johnson S,
Badley EM. Incident myocardial infarction associated
with major types of arthritis in the general population: a
systematic review and meta-analysis. Ann Rheum Dis
2017;76:1396–404.
3 Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni
AA. The impact of traditional cardiovascular risk factors
on cardiovascular outcomes in patients with rheumatoid
arthritis: a systematic review and meta-analysis. PLoS
One 2015;10:e0117952.
4 Wibetoe G, Ikdahl E, Rollefstad S et al. Cardiovascular
disease risk profiles in inflammatory joint disease
entities. Arthritis Res Ther 2017;19:153.
5 Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS
et al. Association of interleukin-6 (IL-6)-174G/C gene
polymorphism with cardiovascular disease in patients
with rheumatoid arthritis: the role of obesity and smok-
ing. Atherosclerosis 2009;204:178–83.
6 Lindhardsen J, Ahlehoff O, Gislason GH et al. The risk
of myocardial infarction in rheumatoid arthritis and
diabetes mellitus: a Danish nationwide cohort study. Ann
Rheum Dis 2011;70:929–34.
7 World Health Organization. WHO report on the global
tobacco epidemic, 2017: monitoring tobacco use and
prevention policies, Geneva: World Health
Organization, 2017. https://apps.who.int/iris/handle/
10665/255874 (18 November 2019, date last accessed).
8 Sugiyama D, Nishimura K, Tamaki K et al. Impact of
smoking as a risk factor for developing rheumatoid
arthritis: a meta-analysis of observational studies. Ann
Rheum Dis 2010;69:70–81.
9 Di Giuseppe D, Discacciati A, Orsini N, Wolk A.
Cigarette smoking and risk of rheumatoid arthritis: a
dose-response meta-analysis. Arthritis Res Ther 2014;
16:R61.
10 Chang K, Yang SM, Kim SH et al. Smoking and
rheumatoid arthritis. Int J Mol Sci 2014;15:22279–95.
11 Malm K, Bremander A, Arvidsson B et al. The
influence of lifestyle habits on quality of life in patients
with established rheumatoid arthritis—a constant
balancing between ideality and reality. Int J Qual Stud
Health Well-Being 2016;11:30534.
12 Combe B, Landewe R, Daien CI et al. 2016 update of
the EULAR recommendations for the management of
early arthritis. Ann Rheum Dis 2017;76:948–59.
13 Agca R, Heslinga SC, Rollefstad S et al. EULAR
recommendations for cardiovascular disease risk
management in patients with rheumatoid arthritis and
other forms of inflammatory joint disorders: 2015/2016
update. Ann Rheum Dis 2017;76:17–28.
14 Piepoli MF, Corra U, Adamopoulos S et al. Secondary
prevention in the clinical management of patients with
cardiovascular diseases. Core components, standards
and outcome measures for referral and delivery: a policy
statement from the cardiac rehabilitation section of the
European Association for Cardiovascular Prevention &
Rehabilitation. Endorsed by the Committee for Practice
Guidelines of the European Society of Cardiology. Eur J
Prev Cardiol 2014;21:664–81.
15 Takata K, Imaizumi S, Kawachi E et al. Impact of
cigarette smoking cessation on high-density lipoprotein
functionality. Circ J 2014;78:2955–62.
16 Forey BA, Fry JS, Lee PN, Thornton AJ, Coombs KJ.
The effect of quitting smoking on HDL-cholesterol – a re-
view based on within-subject changes. Biomarker Res
2013;1:26.
17 Mons U, Muezzinler A, Gellert C et al. Impact of
smoking and smoking cessation on cardiovascular events
and mortality among older adults: meta-analysis of indi-
vidual participant data from prospective cohort studies of
the CHANCES consortium. BMJ 2015;350:h1551.
18 Rigotti NA, Clair C. Managing tobacco use: the
neglected cardiovascular disease risk factor. Eur Heart J
2013;34:3259–67.
19 Kawachi I, Colditz GA, Stampfer MJ et al. Smoking
cessation and time course of decreased risks of
coronary heart disease in middle-aged women. Arch
Intern Med 1994;154:169–75.









atology/kez557/5647348 by guest on 30 N
ovem
ber 2019
20 Joseph RM, Movahedi M, Dixon WG, Symmons DP.
Risks of smoking and benefits of smoking cessation on
hospitalisations for cardiovascular events and respiratory
infection in patients with rheumatoid arthritis: a
retrospective cohort study using the Clinical
Practice Research Datalink. RMD Open 2017;
3:e000506.
21 Crowson CS, Rollefstad S, Ikdahl E et al. Impact of
risk factors associated with cardiovascular outcomes in
patients with rheumatoid arthritis. Ann Rheum Dis 2018;
77:48–54.
22 Crowson CS, Rollefstad S, Kitas GD et al. Challenges
of developing a cardiovascular risk calculator for
patients with rheumatoid arthritis. PLoS One 2017;12:
e0174656.
23 Arnett FC, Edworthy SM, Bloch DA et al. The
American Rheumatism Association 1987 revised criteria
for the classification of rheumatoid arthritis. Arthritis
Rheum 1988;31:315–24.
24 Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid
arthritis classification criteria: an American College of
Rheumatology/European League Against Rheumatism
collaborative initiative. Ann Rheum Dis 2010;69:1580–8.
25 Prevoo ML, van ’t Hof MA, Kuper HH et al. Modified
disease activity scores that include twenty-eight-joint
counts. Development and validation in a prospective lon-
gitudinal study of patients with rheumatoid arthritis.
Arthritis Rheum 1995;38:44–8.
26 Critchley JA, Capewell S. Mortality risk reduction
associated with smoking cessation in patients with
coronary heart disease: a systematic review. JAMA
2003;290:86–97.
27 Ambrose JA, Barua RS. The pathophysiology of
cigarette smoking and cardiovascular disease: an
update. J Am Coll Cardiol 2004;43:1731–7.
28 Sokolove J, Wagner CA, Lahey LJ et al. Increased
inflammation and disease activity among current
cigarette smokers with rheumatoid arthritis: a cross-
sectional analysis of US veterans. Rheumatology 2016;
55:1969–77.
29 Fisher MC, Hochberg MC, El-Taha M et al. Smoking,
smoking cessation, and disease activity in a large cohort
of patients with rheumatoid arthritis. J Rheumatol 2012;
39:904–9.
30 Andersson ML, Bergman S, Soderlin MK. The effect of
stopping smoking on disease activity in rheumatoid
arthritis (RA). Data from BARFOT, a multicenter study of
early RA. Open Rheumatol J 2012;6:303–9.
31 Castaneda S, Martin-Martinez MA, Gonzalez-Juanatey
C et al. Cardiovascular morbidity and associated risk
factors in Spanish patients with chronic inflammatory
rheumatic diseases attending rheumatology clinics:
baseline data of the CARMA Project. Semin Arthritis
Rheum 2015;44:618–26.
32 Gepner AD, Piper ME, Johnson HM et al. Effects of
smoking and smoking cessation on lipids and
lipoproteins: outcomes from a randomized clinical trial.
Am Heart J 2011;161:145–51.
33 Svenson KL, Lithell H, Hallgren R, Vessby B. Serum
lipoprotein in active rheumatoid arthritis and other
chronic inflammatory arthritides. II. Effects of anti-
inflammatory and disease-modifying drug treatment.
Arch Intern Med 1987;147:1917–20.
34 Mallaina P, Lionis C, Rol H et al. Smoking cessation and
the risk of cardiovascular disease outcomes predicted from
established risk scores: results of the Cardiovascular Risk
Assessment among Smokers in Primary Care in Europe
(CV-ASPIRE) study. BMC Public Health 2013;13:362.
35 Iso H, Date C, Yamamoto A et al. Smoking cessation
and mortality from cardiovascular disease among
Japanese men and women: the JACC Study. Am J
Epidemiol 2005;161:170–9.
36 Hjermann I, Velve Byre K, Holme I, Leren P. Effect of
diet and smoking intervention on the incidence of
coronary heart disease. Report from the Oslo Study
Group of a randomised trial in healthy men. Lancet
1981;2:1303–10.
37 Asthana A, Johnson HM, Piper ME et al. Effects of
smoking intensity and cessation on inflammatory
markers in a large cohort of active smokers. Am Heart J
2010;160:458–63.
38 Shiels MS, Katki HA, Freedman ND et al. Cigarette
smoking and variations in systemic immune and
inflammation markers. J Natl Cancer Inst 2014;106.
39 Kool MJ, Hoeks AP, Struijker Boudier HA, Reneman
RS, Van Bortel LM. Short- and long-term effects of
smoking on arterial wall properties in habitual smokers.
J Am Coll Cardiol 1993;22:1881–6.
40 Grassi D, Desideri G, Ferri L et al. Oxidative stress
and endothelial dysfunction: say NO to cigarette
smoking! Curr Pharm Des 2010;16:2539–50.
41 Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF,
Douglas KM et al. Cigarette smoking associates with
body weight and muscle mass of patients with
rheumatoid arthritis: a cross-sectional, observational
study. Arthritis Res Ther 2008;10:R59.
42 Aimer P, Treharne GJ, Stebbings S et al. Efficacy of a
rheumatoid arthritis-specific smoking cessation program:
a randomized controlled pilot trial. Arthritis Care Res
2017;69:28–37.
43 Roelsgaard IK, Thomsen T, Ostergaard M et al. The
effect of an intensive smoking cessation intervention on
disease activity in patients with rheumatoid arthritis:
study protocol for a randomised controlled trial. Trials
2017;18:570.
44 Wong SL, Shields M, Leatherdale S, Malaison E,
Hammond D. Assessment of validity of self-reported
smoking status. Health Rep 2012;23:47–53.
45 Kvalvik LG, Nilsen RM, Skjærven R et al. Self-reported
smoking status and plasma cotinine concentrations
among pregnant women in the Norwegian Mother and
Child Cohort Study. Pediatr Res 2012;72:101–7.
46 Patrick DL, Cheadle A, Thompson DC et al. The
validity of self-reported smoking: a review and meta-ana-
lysis. Am J Public Health 1994;84:1086–93.









atology/kez557/5647348 by guest on 30 N
ovem
ber 2019
